MOMO'S BREAKOUT BOARD

[Captain Hindsight]

$NBIO $NBIO $NBIO

Nascent Biotech Inc. (OTCQB: NBIO)

https://www.nascentbiotech.com/

Nascent Biotech to Sponsor Human Antibodies & Hybridomas Conference
April 4, 2018/in Corporate News /
This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman.

Click this link to download a PDF detailing the conference details, and how to register.


Nascent Biotech is a development stage biopharmaceutical company that develops monoclonal antibodies for the treatment of various forms of cancer. The company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company is primarily focused on developing pritumumab for the treatment of patients with brain cancer malignancies such as glioma and astrocytoma. Pritumumab is a monoclonal antibody that has been tested in Ministry of Health and Welfare approved clinical studies in 249 human brain cancer patients in the nation of Japan. The objective of the Phase I and Phase II human clinical trial was to determine the safety of pritumumab in humans and its efficacy in eliminating tumors or reducing tumor size in patients with brain cancer.

Share Structure
Market Cap
13,785,699
06/07/2018
Authorized Shares
100,000,000
05/31/2018
Outstanding Shares
28,134,079
05/31/2018
Restricted
19,723,969
05/31/2018
Unrestricted
8,410,110
05/31/2018
Held at DTC
3,247,470
05/31/2018
Float
5,056,710
08/07/2017
Par Value
0.00

Recent News

https://finance.yahoo.com/news/nascent-biotech-announces-fast-eligibility-123000444.html

https://finance.yahoo.com/news/nascent-biotech-announces-completion-1-171700110.html